Home › Myelofibrosis › Oregon
Myelofibrosis clinical trials in Oregon
7 studies for Myelofibrosis are looking for participants at sites in Oregon.
Cities in Oregon
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Oregon Health and Science University, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06661915A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
- Site US20, Eugene
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07849231Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Oregon Health and Science University, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05320198A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Willamette Valley Cancer Institute and Research Center, Eugene
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.